Related Experiment Videos
Antithrombin III deficiency.
1Department of Pathology, Medical School, University of Otago, Dunedin, New Zealand.
Blood Reviews
|December 1, 1988
Summary
Reduced antithrombin activity, often due to antithrombin III (AT III) deficiency, can cause severe blood clots. Research has characterized AT III variants and explored recombinant DNA for future treatments and advanced diagnostics.
Area of Science:
- Biochemistry
- Genetics
- Hematology
Background:
- Moderate reduction in plasma antithrombin activity is a rare but significant cause of severe thromboembolic disease.
- Antithrombin III (AT III) has been extensively characterized, with over 30 autosomally dominant inheritable variants identified.
Purpose of the Study:
- To elucidate the molecular basis and inheritance of familial antithrombin deficiencies.
- To explore the potential of recombinant DNA technology for producing functional AT III and advancing diagnostic methods.
Main Methods:
- Gene sequencing of normal human antithrombin III.
- Analysis of familial deficiency inheritance patterns.
- Application of recombinant DNA methods for AT III production.
- Utilizing restriction fragment length polymorphisms and synthetic oligonucleotide probes for diagnostics.
Main Results:
- Detailed characterization of antithrombin III and its variants.
- Insights into the reaction mechanisms between antithrombin, thrombin, and heparin.
- Successful production of functionally active recombinant AT III.
- Development of advanced diagnostic techniques for AT III deficiencies.
Conclusions:
- Understanding antithrombin III structure and function is crucial for managing thromboembolic disorders.
- Recombinant AT III shows promise as a future therapeutic agent.
- Novel diagnostic tools offer improved accuracy and antenatal screening capabilities for hereditary AT III deficiencies.